Stefano Partelli

Stefano Partelli

Auto-generated profile, based on publicly available information

Stefano Partelli

Pancreatic and Transplant Surgery Unit, IRCCS San Raffaele Hospital, Italy

Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 February 2017 in Nature
Verified
Journal Article
Closed access
AIAustralian Pancreatic Cancer Genome Initiative
Australian Pancreatic Cancer Genome Initiative
ASAldo Scarpa
Aldo Scarpa
DCDavid K. Chang
David K. Chang
Katia NonesKatia Nones
Katia Nones
VCVincenzo Corbo
Vincenzo Corbo
SGSean M. Grimmond
Sean M. Grimmond

1 July 2011 in Surgery
Verified
Journal Article
Closed access
RBRossella Bettini
Rossella Bettini
SPStefano Partelli
Stefano Partelli
LBLetizia Boninsegna
Letizia Boninsegna
PCPaola Capelli
Paola Capelli
SCStefano Crippa
Stefano Crippa
MFMassimo Falconi
Massimo Falconi

25 February 2017 in Neuroendocrinology
Verified
Journal Article
Closed access
PDF file
SPStefano Partelli
Stefano Partelli
DBDetlef K. Bartsch
Detlef K. Bartsch
JCJaume Capdevila
Jaume Capdevila
JCJie Chen
Jie Chen
UKUlrich Knigge
Ulrich Knigge
APAll Other Antibes Consensus Conference Participants
All Other Antibes Consensus Conference Participants
The small intestine and pancreas are among the most frequent abdominal sites of origin of neuroendocrine tumours. Distinctive features of these forms are represented by the relatively low incidence and the wide heterogeneity in biological behaviour. In this light, it is difficult to standardize indications for surgery and the most appropriate approach. It would be helpful for surgeons managing patients with these tumours to have guidelines for surgical treatment of small intestinal neuroendocrine tumours and pancreatic neuroendocrine tumours. The proposed guidelines represent a consensus of the working group of the European Neuroendocrine Tumor Society (ENETS).

1 February 2010 in Clinical Gastroenterology and Hepatology
Verified
Journal Article
Closed access
SCStefano Crippa
Stefano Crippa
CCCarlos Fernández–Del Castillo
Carlos Fernández–Del Castillo
RSRoberto Salvia
Roberto Salvia
DFDianne Finkelstein
Dianne Finkelstein
CBClaudio Bassi
Claudio Bassi
AWAndrew L. Warshaw
Andrew L. Warshaw

1 July 2007 in Annals of Surgery
Verified
Journal Article
Closed access
SCStefano Crippa
Stefano Crippa
CBClaudio Bassi
Claudio Bassi
AWAndrew L. Warshaw
Andrew L. Warshaw
MFMassimo Falconi
Massimo Falconi
SPStefano Partelli
Stefano Partelli
CCCarlos Fernández-Del Castillo
Carlos Fernández-Del Castillo
To evaluate the indications, perioperative, and long-term outcomes of a large cohort of patients who underwent middle pancreatectomy (MP). MP is a parenchyma-sparing technique aimed to reduce the risk of postoperative exocrine and endocrine insufficiency. Reported outcomes after MP are conflicting. : Patients who underwent MP between 1990 and 2005 at the Massachusetts General Hospital and at the University of Verona were identified. The outcomes after MP were compared with a control group that underwent extended left pancreatectomy (ELP) for neoplasms in the mid pancreas. A total of 100 patients underwent MP. The most common indications were neuroendocrine neoplasms, serous cystadenoma, and branch-duct IPMNs. Comparison with 45 ELP showed that intraoperative blood loss and transfusions were significantly higher for ELP. The 2 groups showed no differences in overall morbidity, abdominal complications, overall pancreatic fistula, and grade B/C pancreatic fistula rate (17% in MP and 13% in ELP), but the mean hospital-stay was longer for MP patients (P = 0.005). Mortality was zero. In the MP group, 5 patients affected by IPMNs had positive resection margins and 3 had recurrence. After a median follow-up of 54 months, incidence of new endocrine and exocrine insufficiency were significantly higher in the ELP group (4% vs. 38%, P = 0.0001 and 5% vs. 15.6%, P = 0.039, respectively). MP is a safe and effective procedure for treatment of benign and low-grade malignant neoplasms of the mid pancreas and is associated with a low risk of development of exocrine and endocrine insufficiency. MP should be avoided in patients affected by main-duct IPMN.

1 December 2013 in The Journal of Clinical Endocrinology & Metabolism
Verified
Journal Article
Open access
PDF file
SGSebastien Gaujoux
Sebastien Gaujoux
SPStefano Partelli
Stefano Partelli
FMFrédérique Maire
Frédérique Maire
Mirko D'OnofrioMirko D'Onofrio
Mirko D'Onofrio
BLBéatrice Larroque
Béatrice Larroque
PRPhilippe Ruszniewski
Philippe Ruszniewski
Context: Asymptomatic sporadic nonfunctioning, well-differentiated pancreatic neuroendocrine tumors (NF-PNETs) are increasingly diagnosed, and their management is controversial because of their overall good but heterogeneous prognosis. Objective: The objective of the study was to assess the natural history of asymptomatic sporadic NF-PNETs smaller than 2 cm in size and the risk-benefit balance of nonoperative management. Experimental Design: From January 2000 to June 2011, 46 patients with proven asymptomatic sporadic NF-PNETs smaller than 2 cm in size were followed up for at least 18 months with serial imaging in tertiary referral centers. Results: Patients were mainly female (65%), with a median age of 60 years. Tumors were mainly located in the pancreatic head (52%), with a median lesion size of 13 mm (range 9–15). After a median follow-up of 34 months (range 24–52) and an average of four (range 3–6) serial imaging sessions, distant or nodal metastases appeared on the imaging in none of the patients. In six patients (13%), a 20% or greater increase in size was observed. Overall median tumor growth was 0.12 mm per year, and neither patients nor tumor characteristics were found to be significant predictors of tumor growth. Overall, eight patients (17%) underwent surgery after a median time from initial evaluation of 41 months (range 27–58); all resected lesions were European Neuroendocrine Tumor Society T stage 1 (n = 7) or 2 (n = 1), grade 1, node negative, with neither vascular nor peripancreatic fat invasion. Conclusions: In selected patients, nonoperative management of asymptomatic sporadic NF-PNETs smaller than 2 cm in size is safe. Larger and prospective multicentric studies with long-term follow-up are now needed to validate this wait-and-see policy.